Recombinant Human Fms-related Tyrosine Kinase 1, Fc Chimera

• Cat.No.: FLT1-979H
• Product Overview: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1D1-7) produced inInsect cellswas fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1D1-7/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1D1-7/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding.

Specification

• Cat. No.: FLT1-979H
• Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin.
• Source: Insect cells.
• Purity: > 95%, by SDS-PAGE and visualised by silver stain.
• Endotoxin level: < 0.1 ng per μg of sVEGFR-1.
• Stabilizer: None.
• Formulation: Lyophilized.
• Buffer: PBS; pH 7.4.
• Biologically Activity: The activity of sVEGFR-1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml.
• Reconstitution: The lyophilised sVEGFR-1/Fc is soluble in water and most aqueous buffers. The lyophilised sVEGFR-1/Fc should be reconstituted in PBS or medium to a concentration not lower than 50 μg/ml.
• Stability: Lyophilised samples are stable for greater than six months at –20°C to –70°C. Reconstituted sVEGFR-1/Fc should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles!

Gene Information

• Gene Name: FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) [ Homo sapiens ]
• Synonyms: FLT1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); FLT; VEGFR1; vascular endothelial growth factor receptor 1; EC 2.7.10.1; VEGFR-1; Vascular permeability factor receptor; Flt-1; Tyrosine-protein kinase receptor FLT; Tyrosine-protein kinase FRT; Fms-like tyrosine kinase 1; FRT
• Gene ID: 2321
• mRNA Refseq: NM_001159920
• Protein Refseq: NP_001153392
• MIM: 165070
• UniProt ID: P17948
• Chromosome Location: 13q12
• Pathway: Cytokine-cytokine receptor interaction; Endocytosis; Focal adhesion; Signaling by VEGF
• Function: ATP binding; growth factor binding; identical protein binding; nucleotide binding; receptor activity; transferase activity; vascular endothelial growth factor receptor activity